Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 2
1981 1
1982 1
1983 2
1984 1
1990 1
1995 1
2000 3
2006 4
2007 2
2009 2
2011 1
2013 1
2014 4
2015 1
2016 3
2017 5
2018 5
2019 7
2020 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Del Campo JM, et al. Among authors: lesoin a. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173551 Free PMC article. Clinical Trial.
Cancer de l’ovaire : la rechute précoce.
Pautier P, Kalbacher E, de la Motte Rouge T, Bonnetain F, Lesoin A. Pautier P, et al. Among authors: lesoin a. Bull Cancer. 2017 May;104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1. Bull Cancer. 2017. PMID: 28625313 French.
Safety and dose modification for patients receiving niraparib.
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Berek JS, et al. Among authors: lesoin a. Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181. Ann Oncol. 2018. PMID: 29767688 Free article. Clinical Trial.
[Laparoscopic surgery in gynecologic oncology in 2000].
Leblanc E, Querleu D, Castelain B, Lanvin D, Chevalier A, Lesoin A, Gougeon E, Cabaret V, Taïeb S. Leblanc E, et al. Among authors: lesoin a. Bull Cancer. 2000 Jan;87(1):76-85. Bull Cancer. 2000. PMID: 10673635 Free article. Review. French. No abstract available.
Surgical staging of early invasive epithelial ovarian tumors.
Leblanc E, Querleu D, Narducci F, Chauvet MP, Chevalier A, Lesoin A, Vennin P, Taieb S. Leblanc E, et al. Among authors: lesoin a. Semin Surg Oncol. 2000 Jul-Aug;19(1):36-41. doi: 10.1002/1098-2388(200007/08)19:1<36::aid-ssu6>3.0.co;2-e. Semin Surg Oncol. 2000. PMID: 10883022 Review.
Safety and dose modification for patients receiving niraparib.
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Berek JS, et al. Among authors: lesoin a. Ann Oncol. 2019 May 1;30(5):859. doi: 10.1093/annonc/mdy255. Ann Oncol. 2019. PMID: 30107447 Free article. No abstract available.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L. Joly F, et al. Among authors: lesoin a. Gynecol Oncol. 2022 Apr;165(1):30-39. doi: 10.1016/j.ygyno.2022.01.021. Epub 2022 Feb 2. Gynecol Oncol. 2022. PMID: 35123771 Clinical Trial.
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E. Selle F, et al. Among authors: lesoin a. Ann Oncol. 2014 Nov;25(11):2191-2196. doi: 10.1093/annonc/mdu392. Epub 2014 Sep 10. Ann Oncol. 2014. PMID: 25210017 Free article. Clinical Trial.
[Role of laparoscopy in the management of uterine cervix cancer].
Leblanc E, Querleu D, Castelain B, Occelli B, Chauvet MP, Chevalier A, Lesoin A, Vilain MO, Taieb S. Leblanc E, et al. Among authors: lesoin a. Cancer Radiother. 2000 Mar-Apr;4(2):113-21. doi: 10.1016/s1278-3218(00)88894-0. Cancer Radiother. 2000. PMID: 10812356 Review. French.
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
Lee CK, Asher R, Friedlander M, Gebski V, Gonzalez-Martin A, Lortholary A, Lesoin A, Kurzeder C, Largillier R, Hilpert F, Hardy-Bessard AC, Kaminsky MC, Poveda A, Pujade-Lauraine E. Lee CK, et al. Among authors: lesoin a. Eur J Cancer. 2019 Aug;117:99-106. doi: 10.1016/j.ejca.2019.05.029. Epub 2019 Jul 3. Eur J Cancer. 2019. PMID: 31279306 Clinical Trial.
50 results